2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1α.

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Hypoxia-inducible factor 1 (HIF-1) is crucial for tumor survival and progression under hypoxic conditions.
• HIF-1 is a promising therapeutic target for cancer treatment.
• Existing HIF-1 inhibitors are primarily synthetic compounds.

Purpose of the Study:

• To identify and characterize novel natural compounds with HIF-1 inhibitory activity.
• To investigate the mechanism of action of Actinolactomycin (ALM) on HIF-1α.
• To evaluate the anti-cancer potential of ALM in vitro and in vivo.

Main Methods:

• Extraction and identification of ALM from Streptomyces flavoretus metabolites.
• Assessment of ALM's effect on HIF-1α protein translation and mTOR signaling.
• In vitro and in vivo studies evaluating ALM's efficacy in cancer models.
• Combination therapy studies with Everolimus.

Main Results:

• ALM, a natural compound, was identified as an inhibitor of HIF-1α translation.
• ALM suppresses HIF-1α protein synthesis by inhibiting mTOR signaling.
• ALM demonstrated significant in vitro and in vivo anti-cancer effects, including apoptosis induction and growth inhibition.
• Low-dose ALM enhanced the anti-tumor efficacy of Everolimus, an mTOR inhibitor.

Conclusions:

• Actinolactomycin (ALM) is a novel HIF-1α inhibitor derived from natural sources.
• ALM exhibits anti-cancer properties through HIF-1α dependent mechanisms.
• ALM holds potential for cancer therapy, particularly in combination with mTOR inhibitors like Everolimus for solid tumors.